Evaluation of Duodenal Mucosal Resurfacing (DMR) for the Treatment of Non Alcoholic Steatohepatitis (NASH), a Proof of Concept Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 14
- 试验地点
- 2
- 主要终点
- Safety of duodenal mucosal resurfacing characterized by the incidence of all Adverse Device Effects (ADEs), and subsequent adverse events [ Time Frame: 12 months ] in patients with NASH.
研究概览
简要总结
Non-alcoholic fatty liver disease (NAFLD) is a frequent disease affecting up to 25% of the USA population, 2-44% in Europe and up to 42,6-69,5% in patients with type 2 diabetes. It is a disease that could progress from simple steatosis to non-alcoholic steatohepatitis (NASH), hepatic cirrhosis and hepatocarcinoma. NASH is part of continuum of metabolic syndrome and constitutes a serious public health concern manifesting by premature cardiovascular disease, end stage diabetes complication and will likely become the first cause of end stage liver disease. Insuline resistance is the hallmark of NASH. Some recent studies both in animals and humans have demonstrated abnormal hypertrophy of the duodenal mucosa, changes in enteroendocrine cell density and number, endocrine hyperplasia, and alterations in gut hormone signaling highlighting the role of the upper intestine gut in glucose homeostasis and thus insulin sensitizing. Given these physiological and pathophysiological features, abrasion of duodenal mucosa was assessed both in animals and humans. The investigators reported an improvement in both glucose homeostasis and transaminases levels suggesting possibly an improvement of NASH. Until now, lifestyle medication is the only recognized efficient treatment for fatty liver disease. Unfortunately, only a minority of patients achieve a significant weight loss and lifestyle modifications. The investigators aim to study the duodenal mucosal resurfacing procedure in patients with NASH biopsy proven in a proof of concept study allowing to assess this technique as a potential treatment to NASH.
详细描述
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a frequent disease affecting up to 25% of the USA population, 2-44% in Europe and up to 42,6-69,5% in patients with type 2 diabetes. It is a disease that could progress from simple steatosis to non-alcoholic steatohepatitis (NASH), hepatic cirrhosis and hepatocarcinoma. NASH is part of continuum of a metabolic syndrome and constitutes a serious public health concern, manifesting by premature cardiovascular disease, end stage diabetes complication and will likely become the first cause of end stage liver disease.
Insulin resistance is the hallmark of NASH. Some recent studies both in animals and humans have demonstrated abnormal hypertrophy of the duodenal mucosa, changes in enteroendocrine cell density and number, endocrine hyperplasia, and alterations in gut hormone signaling highlighting the role of the upper intestine gut in glucose homeostasis and thus insulin sensitizing.
Given these physiological and pathophysiological features, abrasion of duodenal mucosa was assessed both in animals and humans. The investigators reported an improvement in both glucose homeostasis and transaminases levels suggesting possibly an improvement of NASH.
Until now, lifestyle medication is the only recognized efficient treatment for fatty liver disease. Unfortunately, only a minority of patients achieve a significant weight loss and lifestyle modifications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 28 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult subjects (male and female), age 28 to 75 years.
- •NASH histological diagnosis according to the currently accepted definition of both EASL and AASLD, requiring the combined presence of steatosis (any degree> 5%) + lobular inflammation of any degree + liver cell ballooning of any amount, on a liver biopsy performed ≤ 6 months before screening in the study and confirmed by central reading during the periode and (apendix 1)
- •SAF (steatosis, activity, fibrosis) activity score of 3 or 4 (>2)
- •SAF steatosis score ≥ 1
- •SAF fibrosis score < 4
- •No other causes of chronic liver disease and compensated liver disease.
- •If applicable, have a type 2 diabetes with HbA1c <10.0 %
- •BMI (body mass index) ≥ 24 and ≤ 40 kg/m
- •Willing to sign an informed consent form.
- •Willing to comply with study requirements
排除标准
- •Evidence of another cause of liver disease.
- •History of sustained alcohol ingestion defined as: daily alcohol consumption > 30 g/day for males and > 20 g/day for females.
- •Previous gastrointestinal surgery such as subjects who have had Billroth 2, Roux-en-Y gastric bypass, or other similar procedures or conditions.
- •Known autoimmune disease, including celiac disease, or symptoms of systemic lupus eythematosus, sleroderma or other auto-immune connective tissue disorder.
- •For type 2 diabetes subjects, no current use of insulin or GLP-1 analogues.
- •Type 1 diabetes.
- •Probable insulin production failure defined as fasting C peptide serum < 1 ng/ml.
- •History of acute or chronic pancreatitis.
- •Active malignancy.
- •Persistent anemia defined as Hb < 10 g/dl.
- •Use of anticoagulation therapy which cannot be discontinued for 7 days before and 14 days after the procedure.
- •Use of P2Y12 inhibitors (clopidrogel, prasugrel, ticagrelor) which cannot be discontinued for 14 days before and14 days after the procedure.
- •History of coagulopathy or upper gastro-intestinal bleeding conditions likely to bleed.
- •Taking corticosteroids or drugs which possibly affect gastrointestinal motility or liver.
- •Unable to discontinue NSAIDs (non-steroidal anti- inflammatory drugs) during the treatment up to 4 weeks after procedure.
- •Use of weight loss medications.
- •Presence of liver cirrhosis (defined by histology)
- •Platelet count < 120 x 109/L.
- •Clinical evidence of hepatic decompensation or severe liver impairment as defined by the presence of any of the following abnormalities:
- •Serum albumin < 32 g/L.
- •Direct bilirubin> 1.3 mg/L.
- •ALT or AST > 5x ULN.
- •Alkaline Phosphatase > 3x ULN.
- •History of esophageal varices, ascites or hepatic encephalopathy.
- •Splenomegaly.
- •Human immunodeficiency virus.
- •Contraindications to MRI as defined below.
结局指标
主要结局
Safety of duodenal mucosal resurfacing characterized by the incidence of all Adverse Device Effects (ADEs), and subsequent adverse events [ Time Frame: 12 months ] in patients with NASH.
时间窗: 12 months
Safety will be characterized by the incidence of all Adverse Device Effects (ADEs), non-serious and serious, possibly related to or related to the procedure and/or device that are experienced by study participants. Safety evaluations will also be performed to ensure no subsequent adverse events have occurred and to ensure any adverse events during the trial that are considered on-going are stable or have resolved. Safety will be assessed at 1 and 6 months following the intervention.
次要结局
- Change in NAS score from baseline in the following 12 months in DMR subjects.(baseline and 12 months post-procedure)
- Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 12 months in DMR subjects(baseline and 12 months post-procedure)
- Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following 6 months in DMR subjects.(baseline and 6 months post-procedure)
- Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following 12 months in DMR subjects.(baseline and 12 months post procedure)
- Change in Insulin resistance measured by oral glucose tolerance test (OGTT) from baseline in the following 6 months in DMR subjects(baseline and 6 months post-procedure)
- Change in Transient Elastography using Firboscan from baseline in the following at 6 months in DMR subjects(baseline and 6 months post-procedure)
- Change in Transient Elastography using Firboscan from baseline in the following at 12 months in DMR subjects(baseline and 12 months post-procedure)
- Change in Insulin resistance measured by oral glucose tolerance test (OGTT) from baseline in the following 12 months in DMR subjects(baseline and 12 months post procedure)
- Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 6 months in DMR subjects(baseline and 6 months post-procedure)
- Change in transaminases levels from baseline in the following 6 months in DMR subjects(baseline and 6 months post-procedure)
- Change in transaminases levels from baseline in the following 12 months in DMR subjects(baseline and 12 months post-procedure)
- Change in stage of fibrosis from baseline in the following 12 months in DMR subjects(baseline and 12 months post-procedure)